Compare SLQT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | RNXT |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 79.4M |
| IPO Year | 2020 | 2021 |
| Metric | SLQT | RNXT |
|---|---|---|
| Price | $0.36 | $1.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.09 | ★ $7.13 |
| AVG Volume (30 Days) | ★ 1.2M | 403.6K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,618,499,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | $4.88 | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.02 | ★ 2511.63 |
| 52 Week Low | $0.30 | $0.70 |
| 52 Week High | $2.17 | $2.59 |
| Indicator | SLQT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 51.70 |
| Support Level | N/A | $0.83 |
| Resistance Level | $0.78 | $1.51 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 94.17 | 81.08 |
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. Its insurance distribution business allows consumers to transparently and conveniently shop for senior health, life, and automobile and home insurance policies from a curated panel of the nation's insurance carriers. It operates in three reportable segments: Senior, Healthcare Services, and Life. Senior sells senior Medicare-related health insurance products. Healthcare Services includes SelectRx, Healthcare Select, and SPM. Healthcare Services provides products and services to its Medicare policyholders, which are focused on improving patient health outcomes. Life sells term life and final expense products.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.